Addgene: Loss of LRRC33-dependent TGFbeta1 activation enhances anti-tumor immunity and checkpoint blockade therapy.

This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Browse
Timothy Springer
Jiang et al

Loss of LRRC33-dependent TGFbeta1 activation enhances anti-tumor immunity and checkpoint blockade therapy.
Jiang A, Qin Y, Springer TA
Cancer Immunol Res. 2022 Feb 18. pii: 681626. doi: 10.1158/2326-6066.CIR-21-0593. PubMed Article

Plasmids from Article

ID	Plasmid	Purpose
180258	pD2529-CAG-HA-mouse GARP	Mouse full length GARP expression
180259	pD2529-CAG-HA-mouse LRRC33	Mouse full length LRRC33 expression
180260	pD2529-CAG-Flag-mouse TGFb1	Mouse full length TGFβ1 expression
180261	PD2529-CAG-Flag-mouse TGFb2	Mouse full length TGFβ2 expression
180262	pD2529-CAG-Flag-mouse TGFb3	Mouse full length TGFβ3 expression

Plasmids from Article

Antibodies from Article

Help Center

Deposit Plasmids

General Reagents

Viral Service

DNA Service

Plasmid Collections

	More than 20 requests
	More than 50 requests
	More than 100 requests